Gossamer bio and chiesi group announce transformative global collaboration to develop and commercialize seralutinib in pah, ph-ild & other indications

San diego, calif. & parma, italy--(business wire)---- $goss--gossamer bio, inc. (“gossamer”) (nasdaq: goss), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension, and chiesi farmaceutici s.p.a (“chiesi group”), an international, research-focused biopharmaceutical group, today announced that they have entered into a global collaboration and license agreement to develop and commercialize seralutinib. this glob.
GOSS Ratings Summary
GOSS Quant Ranking